Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 59
Filter
1.
Mutat Res ; 493(1-2): 139-47, 2001 Jun 27.
Article in English | MEDLINE | ID: mdl-11516723

ABSTRACT

The topoisomerase II inhibitor etoposide is used routinely to treat a variety of cancers in patients of all ages. As a result of its extensive use in the clinic and its association with secondary malignancies it has become a compound of great interest with regard to its genotoxic activity in vivo. This paper describes a series of assays that were employed to determine the in vivo genotoxicity of etoposide in a murine model system. The alkaline comet assay detected DNA damage in the bone marrow mononuclear compartment over the dose range of 10--100mg/kg and was associated with a large and dose dependent rise in the proportion of cells with severely damaged DNA. In contrast, the bone marrow micronucleus assay was found to be sensitive to genotoxic damage between the doses of 0.1--1mg/kg without any corresponding increases in cytotoxicity. An increase in the mutant frequency was undetectable at the Hprt locus at administered doses of 1 and 10mg/kg of etoposide, however, an increase in the mutant frequency was seen at the Aprt locus at these doses. We conclude that the BMMN assay is a good short-term predictor of the clastogenicity of etoposide at doses that do not result in cytotoxic activity, giving an indication of potential mutagenic effects. Moreover, the detection of mutants at the Aprt locus gives an indication of the potential of etoposide to cause chromosomal mutations that may lead to secondary malignancy.


Subject(s)
Etoposide/toxicity , Mutagenicity Tests/methods , Mutagens/toxicity , Adenine Phosphoribosyltransferase/genetics , Animals , Antineoplastic Agents, Phytogenic/toxicity , Comet Assay , Humans , Hypoxanthine Phosphoribosyltransferase/genetics , In Situ Hybridization, Fluorescence , Male , Mice , Micronucleus Tests , Spleen/drug effects , Spleen/enzymology , Topoisomerase II Inhibitors
2.
Leukemia ; 14(10): 1796-802, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11021755

ABSTRACT

We have used the bone marrow micronucleus assay (BMMN) as a measure of clastogenicity, in response to etoposide exposure in murine bone marrow. Oral delivery of etoposide resulted in a reduced number of micronucleated polychromatic erythrocytes (MPE) relative to the same dose delivered intraperitoneally (P < 0.001). Daily fractionation of the oral schedule of etoposide led to a more than six-fold increase in cumulative MPE frequency over that observed with the same total, unfractionated dose, with the potency of the response increasing with serial exposure (r = 0.79). Retrovirally-mediated expression of MDR1 in murine bone marrow resulted in partial protection against the clastogenic activity of etoposide relative to mock transduced control mice. The model system developed has indicated a variety of factors able to influence the genotoxicity of etoposide. It should now be possible to further exploit this model in order to define other factors governing haemopoietic sensitivity to etoposide.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , Antineoplastic Agents, Phytogenic/pharmacology , Bone Marrow/drug effects , Etoposide/pharmacology , Gene Transfer, Horizontal , Animals , Antineoplastic Agents, Phytogenic/administration & dosage , Drug Administration Routes , Drug Administration Schedule , Etoposide/administration & dosage , Female , Male , Mice , Micronucleus Tests
3.
Bone Marrow Transplant ; 25 Suppl 2: S110-3, 2000 May.
Article in English | MEDLINE | ID: mdl-10933202

ABSTRACT

Many of the problems with current anti-tumour therapies stem from a lack of specificity for tumour as opposed to normal tissues. To address the problem of collateral toxicity during anti-tumour chemotherapy we have been developing a gene therapy approach to protect normal tissues from the toxic and potentially mutagenic effects of chemotherapeutic agents. As a paradigm for this we have been examining the potential of the DNA repair protein O6-alkylguanine-DNA-alkyltransferase (ATase) to confer genetic chemoprotection to the bone marrow. By transfer and expression of a mutant form of this protein, which is resistant to inactivation by the tumour sensitising agent O6-benzylguanine (O6-beG), we have been able to demonstrate protection of murine bone marrow in vitro from the cytotoxic and clastogenic effects of O6-beG in combination with the anti-tumour agent temozolomide. This protection is seen in multiple lineages, including erythroid and granulocyte/macrophage progenitors, as well as more primitive cells. Importantly, significant protection of the platelet lineage is also seen, with faster recovery of platelets. The multi-lineage protection seen has encouraged us to take this approach forward to clinical trial in the near future.


Subject(s)
Drug Resistance/genetics , Genetic Engineering , Animals , Antineoplastic Agents/adverse effects , Bone Marrow/drug effects , Bone Marrow Transplantation , DNA Repair/genetics , Female , Genetic Therapy/methods , Humans , Male , Mice , Neoplasms/drug therapy , Neoplasms/genetics , Neoplasms/therapy , O(6)-Methylguanine-DNA Methyltransferase/genetics
4.
J Reprod Fertil ; 119(2): 339-46, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10864847

ABSTRACT

The O(6)-alkylguanine-DNA alkyltransferase inactivator O(6)-benzylguanine was administered to BALB/c mice either alone or before exposure to 1,3-bis(2-chloroethyl)-1-nitrosourea to study the role of the DNA repair protein O(6)-alkylguanine-DNA alkyltransferase in the protection of the testis against anti-cancer O(6)-alkylating agents. Exposure of the mice to 1, 3-bis(2-chloroethyl)-1-nitrosourea or O(6)-benzylguanine alone did not produce any marked testicular toxicity at the times studied. Testicular O(6)-alkylguanine-DNA alkyltransferase concentrations were assayed between 0 and 240 min after O(6)-benzylguanine treatment and were shown to be > 95% depleted 15 min after treatment with O(6)-benzylguanine and remained at > 95% at all the times assayed. Histological examination, the reduction in testicular mass and the induction of spermatogenic cell apoptosis showed that this depletion significantly potentiated 1, 3-bis(2-chloroethyl)-1-nitrosourea-induced testicular damage after treatment. Major histological damage was apparent 42 days after treatment, demonstrating that the stem spermatogonia were significantly affected by the combination. These results demonstrate that O(6)-alkylguanine-DNA alkyltransferase plays a significant role in protecting the spermatogenic cells from damage caused by DNA alkylation and indicate that the observed toxicity may result from damage to stem spermatogonia.


Subject(s)
Antineoplastic Agents, Alkylating/toxicity , Carmustine/toxicity , Guanine/analogs & derivatives , O(6)-Methylguanine-DNA Methyltransferase/antagonists & inhibitors , O(6)-Methylguanine-DNA Methyltransferase/physiology , Seminiferous Epithelium/enzymology , Spermatogonia/drug effects , Analysis of Variance , Animals , Antineoplastic Agents, Alkylating/pharmacokinetics , Apoptosis/drug effects , Carmustine/pharmacokinetics , DNA Repair/drug effects , Drug Resistance , Enzyme Inhibitors/pharmacology , Guanine/pharmacology , Half-Life , In Situ Nick-End Labeling , Male , Mice , Mice, Inbred BALB C , Seminiferous Epithelium/drug effects , Seminiferous Epithelium/pathology , Spermatogonia/pathology , Testis/drug effects , Testis/enzymology , Testis/pathology , Time Factors
5.
Haematologica ; 85(5): 451-7, 2000 May.
Article in English | MEDLINE | ID: mdl-10800158

ABSTRACT

BACKGROUND AND OBJECTIVE: As a single gene defect in mature bone marrow cells, chronic granulomatous disease (X-CGD) represents a disorder which may be amenable to gene therapy by the transfer of the missing subunit into hemopoietic stem cells. In the majority of cases lack of Gp91-phox causes the disease. So far, studies involving transfer of Gp91-phox cDNA, including a phase I clinical trial, have yielded disappointing results. Most often, low titers of virus have been reported. In the present study we investigated the possible reasons for low titer amphotropic viral production. DESIGN AND METHODS: To investigate the effect of Gp91 cDNA on the efficiency of retroviral production from the packaging cell line, GP+envAm12, we constructed vectors containing either the native cDNA, truncated versions of the cDNA or a mutated form (LATG) in which the natural translational start codon was changed to a stop codon. Following derivation of clonal packaging cell lines, these were assessed for viral titer by RNA slot blot and analyzed by non-parametrical statistical analysis (Whitney-Mann U-test). RESULTS: An improvement in viral titer of just over two-fold was found in packaging cells containing the start-codon mutant of Gp91 and no evidence of truncated viral RNA was seen in these cells. Further analysis revealed the presence of rearranged forms of the provirus in Gp91-expressing cells, and the production of truncated, unpackaged viral RNA. Protein analysis revealed that LATG-transduced cells did not express full-length Gp91-phox, whereas those containing the wild-type cDNA did. However, a truncated protein was seen in ATG-transduced cells which was also present in wild type cells. No evidence for the presence of a negative transcriptional regulatory element was found from studies with the deletion mutants. INTERPRETATION AND CONCLUSIONS: A statistically significant effect of protein production on the production of virus from Gp91-expressing cells was found. Our data point to a need to restrict expression of the Gp91-phox protein and its derivatives in order to enhance retroviral production and suggest that improvements in current vectors for CGD gene therapy may need to include controlled, directed expression only in mature neutrophils.


Subject(s)
Membrane Glycoproteins/genetics , NADPH Oxidases , Retroviridae/growth & development , 3T3 Cells , Animals , Blotting, Northern , Blotting, Southern , Blotting, Western , DNA, Complementary/genetics , Gene Transfer Techniques/standards , Genetic Vectors/chemistry , Humans , Membrane Glycoproteins/pharmacology , Mice , NADPH Oxidase 2 , RNA, Viral/biosynthesis , Retroviridae/drug effects , Retroviridae/genetics , Viral Proteins/analysis
6.
Cancer Gene Ther ; 7(2): 233-9, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10770631

ABSTRACT

Retroviral gene transfer was used to achieve expression in mouse bone marrow of a mutant form of the DNA repair protein O6-alkylguanine-DNA alkyltransferase (hATPA/GA), which exhibits resistance to inactivation by O6-benzylguanine (O6-beG). After reconstitution of mice with transduced bone marrow, approximately 50% of the bipotent granulocyte-macrophage colony-forming cell (GM-CFC) and multipotent spleen colony-forming unit (CFU-S) hemopoietic populations showed expression of the transgene; this expression was associated with resistance to either mitozolomide or to a combination of O6-beG and mitozolomide, relative to mock-transduced controls. Thus, at a dose of mitozolomide in vivo that allowed only 70% and 62% survival of mock-transduced GM-CFC and CFU-S, respectively, the hATPA/GA CFC were totally resistant to the same dose of mitozolomide (P < .05 and .001, respectively). In the presence of O6-beG, the toxicity of mitozolomide was greatly potentiated. Only 24% and 18%, respectively, of mock-transduced GM-CFC and CFU-S survived combination treatment, whereas 45% (P < .05) and 37% (P < .01) of GM-CFC and CFU-S, respectively, from hATPA/GA mice survived the same combination of doses. Furthermore, as a result of transgene expression, the number of micronucleated polychromatic erythrocytes induced by mitozolomide was significantly reduced (P < .05) by 40% relative to mock-transduced controls, indicating the potential of this approach to reduce the frequency of mutation associated with chemotherapy exposure. The protection against the toxic and clastogenic effects of mitozolomide in both primitive and more mature hemopoietic cells suggests that the severe myelosuppression that halted further clinical investigation of this drug could be substantially ameliorated by the exogenous expression of O6-alkylguanine-DNA alkyltransferase. Therefore, these data raise the prospect for the reinvestigation of mitozolomide and other proscribed drugs in the context of genetically protected hemopoiesis.


Subject(s)
Antineoplastic Agents/pharmacology , Drug Resistance, Neoplasm , Hematopoietic Stem Cells/drug effects , Nitrogen Mustard Compounds/pharmacology , Animals , Bone Marrow Cells/cytology , Bone Marrow Cells/drug effects , Bone Marrow Transplantation , Colony-Forming Units Assay , Drug Resistance, Neoplasm/genetics , Drug Synergism , Gene Transfer Techniques , Male , Mice , Mice, Inbred C57BL , Mice, Inbred DBA , Mutagens/pharmacology , O(6)-Methylguanine-DNA Methyltransferase/biosynthesis , O(6)-Methylguanine-DNA Methyltransferase/genetics , Retroviridae/genetics
7.
Gene Ther ; 6(8): 1489-93, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10467374

ABSTRACT

Following transduction with a retrovirus (SF1MIH) expressing both the multidrug resistance 1 (MDR1) and O6-alkylguanine-DNA-alkyltransferase (ATase) proteins, human erythroleukaemic progenitor (K562) cells were isolated which were resistant to killing by the MDR1 substrate, colchicine. In colony-forming survival assays, K562-SF1MIH cells exhibited resistance to colchicine and doxorubicin, as well as to the O6-alkylating agents N-Methyl-N-nitrosourea (MNU) and temozolomide. Furthermore, the resistance to doxorubicin was abolished by preincubation with the MDR1 inhibitor verapamil while resistance to MNU was ablated by the specific ATase inactivator, O6-benzylguanine (O6-beG) confirming that resistance to doxorubicin and MNU was conferred by MDR1 and ATase, respectively. When K562-SF1MIH were exposed to combinations of colchicine and MNU or doxorubicin and temozolomide, simultaneous resistance to these agents was observed. Thus, transduction of K562 with SF1MIH conferred dual resistance to these cells. These data offer the prospect of designing vectors that will confer resistance to entire regimens of chemotherapy rather than just to individual components of such drug cocktails, thereby substantially increasing the efficacy of therapy. Furthermore, the use of such dual expression constructs is likely to be highly informative for the design of effective in vivo selection protocols, an issue likely to make a major impact in a clinical context in gene therapy in the near future.


Subject(s)
Antineoplastic Agents/therapeutic use , Drug Resistance, Multiple/genetics , Hematopoietic Stem Cells/physiology , O(6)-Methylguanine-DNA Methyltransferase/genetics , Retroviridae/genetics , Transduction, Genetic/genetics , Drug Resistance, Neoplasm/genetics , Genes, MDR/genetics , Genetic Vectors , Hematopoietic Stem Cells/enzymology , Humans , K562 Cells , O(6)-Methylguanine-DNA Methyltransferase/metabolism , Retroviridae/enzymology
8.
Mutat Res ; 444(1): 175-80, 1999 Jul 21.
Article in English | MEDLINE | ID: mdl-10477352

ABSTRACT

The clastogenicity of the azo dye Direct Red 2 (DR2) has been investigated using the murine bone marrow micronucleus assay. A potent dose-dependent response was observed following oral gavage of DR2 up to 4 mg/kg, after which significant toxicity to the erythroid compartment was observed. The route of administration had a significant effect on the frequency of micronucleus formation: intraperitoneal injection was approximately two-fold less clastogenic than the equivalent dose delivered orally (p<0.05). The requirement for activation of DR2 by intestinal microflora was indicated by the fact that mice given acid-treated water prior to administration of DR2 showed a significant reduction (40%; p<0.001) in micronucleated polychromatic erythrocyte formation. The implications of these findings for the health and safety of occupationally exposed workers are discussed.


Subject(s)
Azo Compounds/toxicity , Coloring Agents/toxicity , Mutagens/toxicity , Naphthalenesulfonates/toxicity , Animals , Azo Compounds/administration & dosage , Azo Compounds/pharmacokinetics , Biotransformation , Bone Marrow Cells/drug effects , Coloring Agents/administration & dosage , Coloring Agents/pharmacokinetics , Dose-Response Relationship, Drug , Humans , Intestinal Mucosa/metabolism , Intestines/microbiology , Male , Mice , Micronucleus Tests , Mutagens/administration & dosage , Mutagens/pharmacokinetics , Naphthalenesulfonates/administration & dosage , Naphthalenesulfonates/pharmacokinetics , Public Health
9.
Br J Cancer ; 80(7): 940-5, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10362100

ABSTRACT

Apurinic/apyrimidinic (AP) sites in DNA are potentially lethal and mutagenic. They can arise spontaneously or following DNA damage from reactive oxygen species or alkylating agents, and they constitute a significant product of DNA damage following cellular exposure to ionizing radiation. The major AP endonuclease responsible for initiating the repair of these and other DNA lesions in human cells is HAP1, which also possesses a redox function. We have determined the cellular levels of this enzyme in 11 human tumour and fibroblast cell lines in relation to clonogenic survival following ionizing radiation. Cellular HAP1 levels and surviving fraction at 2 Gy (SF2) varied five- and tenfold respectively. However, no correlation was found between these two parameters following exposure to gamma-irradiation at low (1.1 cGy per min) or high (108 cGy per min) dose rates. To examine this further, wild-type and mutant versions of HAP1 were overexpressed, using an inducible HAP1 cDNA expression vector system, in the rat C6 glioma cell line which has low endogenous AP endonuclease activity. Induction of wild-type HAP1 expression caused a > fivefold increase in the capacity of cellular extracts to cleave an oligonucleotide substrate containing a single abasic site, but increased expression did not confer increased resistance to gamma-irradiation at high- or low-dose rates, or to the methylating agent methyl methanesulphonate (MMS). Expression in C6 cell lines of mutant forms of HAP1 deleted for either the redox activator or DNA repair functions displayed no apparent titrational or dominant negative effects. These studies suggest that the levels of endogenous AP endonuclease activities in the various cell lines examined are not limiting for efficient repair in cells following exposure to ionizing radiation or MMS. This contrasts with the correlation we have found between HAP1 levels and radiosensitivity in cervix carcinomas (Herring et al (1998) Br J Cancer 78: 1128-1133), indicating that HAP1 levels in this case assume a critical survival role and hence that established cell lines might not be a suitable model for such studies.


Subject(s)
Carbon-Oxygen Lyases/biosynthesis , DNA Repair/radiation effects , Neoplasms/enzymology , Animals , Carbon-Oxygen Lyases/genetics , Cell Survival/radiation effects , DNA-(Apurinic or Apyrimidinic Site) Lyase , Deoxyribonuclease IV (Phage T4-Induced) , Dose-Response Relationship, Radiation , Gamma Rays , Gene Expression , Glioma/enzymology , Glioma/genetics , Glioma/pathology , Humans , Immunoblotting , Neoplasms/genetics , Radiation Tolerance , Rats , Transfection , Tumor Cells, Cultured
10.
Br J Cancer ; 79(9-10): 1332-9, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10188873

ABSTRACT

Previous studies have demonstrated that novel molecular combinations of 5-fluorouracil (5FU) and 2-chloroethyl-1-nitrosourea (CNU) have good preclinical activity and may exert less myelotoxicity than the clinically used nitrosoureas such as 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). This study examined the effect of O6-alkylguanine-DNA-alkyltransferase (ATase) depletion by the pseudosubstrate O6-benzylguanine (BG) on the anti-tumour activity and normal tissue toxicity in mice of three such molecular combinations, in comparison with BCNU. When used as single agents at their maximum tolerated dose, all three novel compounds produced a significant growth retardation of BCNU-resistant murine colon and human breast xenografts. This in vivo anti-tumour effect was potentiated by BG, but was accompanied by severe myelotoxicity as judged by spleen colony forming assays. However, while tumour resistance to BCNU was overcome using BG, this was at the expense of enhanced bone marrow, gut and liver toxicity. Therefore, although this ATase-depletion approach resulted in improved anti-tumour activity for all three 5-FU:CNU molecular combinations, the potentiated toxicities in already dose-limiting tissues indicate that these types of agents offer no therapeutic advantage over BCNU when they are used together with BG.


Subject(s)
Antineoplastic Agents, Alkylating/pharmacology , Carmustine/pharmacology , Enzyme Inhibitors/pharmacology , Ethylnitrosourea/analogs & derivatives , Fluorouracil/pharmacology , Guanine/analogs & derivatives , O(6)-Methylguanine-DNA Methyltransferase/metabolism , Animals , Antineoplastic Agents, Alkylating/adverse effects , Antineoplastic Agents, Alkylating/chemistry , Carmustine/adverse effects , Colony-Forming Units Assay , Drug Combinations , Drug Resistance, Neoplasm , Ethylnitrosourea/chemistry , Ethylnitrosourea/pharmacology , Fluorouracil/chemistry , Guanine/pharmacology , Humans , Male , Mice , Mice, Nude , Tumor Stem Cell Assay
11.
Hum Gene Ther ; 10(2): 301-10, 1999 Jan 20.
Article in English | MEDLINE | ID: mdl-10022554

ABSTRACT

Recombinant adeno-associated virus (rAAV) encoding the human O6-alkylguanine-DNA-alkyltransferase (hAT) protein and a selectable marker (Neo(r)) was used to transduce human cervical carcinoma (HeLa) cells and erythroleukemic (K562) cells and clones were selected using G418 (0.4 mg/ml). Thirteen HeLa clones were isolated, 9 of which survived for 2-3 months before cell death ensued, presumably owing to the loss of G418 resistance. Northern blot analysis of the remaining four clones, using a neo probe, showed high levels of RNA equivalent in size to the bicistronic RNA expected to be produced from this construct. Analysis of hAT activity showed that 2000-5000 fmol/mg protein was expressed relative to untransduced cells (800-900 fmol/mg protein). Cell survival analysis following exposure to the chloroethylating agent mitozolomide revealed that expression of hAT at levels two- to fourfold higher than background conferred significant resistance (p < 0.001) to the toxic effects of this drug. Two days following infection of K562 cells with the rAAV vector, immunoblot analysis showed that hAT protein was being produced. Three K562 clones, isolated using G418 selection, were studied in detail and were shown to express hAT activities of 1500, 1010, and 890 fmol/mg protein, respectively, at 40 days posttransduction (mock-transduced K562 cells contain <2 fmol of hAT/mg protein). As with HeLa cells, Northern blot analysis showed the production of an appropriately sized transcript and immunoblot analysis indicated that hAT protein was being produced. These clones were assayed for cell survival following exposure to mitozolomide. Expression of hAT at levels 800- to 1500-fold higher than background conferred significant resistance (p < 0.001) to the toxic effects of mitozolomide. We have therefore successfully conferred a protective advantage against mitozolomide toxicity to cells by rAAV-mediated hAT expression.


Subject(s)
Antineoplastic Agents, Alkylating/toxicity , Dependovirus/genetics , Hematopoietic Stem Cells/drug effects , Nitrogen Mustard Compounds/toxicity , O(6)-Methylguanine-DNA Methyltransferase/genetics , Base Sequence , DNA Primers , Epithelium/drug effects , Humans , Plasmids , Recombination, Genetic , Transduction, Genetic , Transgenes , Tumor Cells, Cultured
12.
Expert Rev Mol Med ; 1999: 1-28, 1999 Aug 12.
Article in English | MEDLINE | ID: mdl-14987353

ABSTRACT

The effectiveness of anti-cancer chemotherapy can be limited by acute suppression of the bone marrow (myelosuppression). There is also a risk of therapy-related secondary haematopoietic malignancy as well as acute and longer term effects in other tissues. Clinical strategies have been established to address some of these problems, particularly toxic effects on the bone marrow (acute myelotoxicity); however, there is still substantial scope for improving the management of chronic toxicity and mutagenicity to haematopoietic cells and collateral damage to non-haematopoietic cells during chemotherapy. In this review, we have discussed a novel strategy that involves the transfer and expression of drug-resistance functions into haematopoietic stem cells and more-mature blood progenitor cells, to overcome both the acute and long-term deleterious effects of anti-tumour treatment in bone marrow. The potential advantages of this approach include: (1) the in vivo selection of protected cell populations, which offers the possibility of intensification or escalation of chemotherapeutic drug doses; (2) a reduction in the frequency of therapy-related leukaemia and (3) tumour sensitisation to chemotherapy at the same time as haematopoietic protection.

13.
Stem Cells ; 16(6): 387-96, 1998.
Article in English | MEDLINE | ID: mdl-9831864

ABSTRACT

The AC133 antigen is a novel antigen selectively expressed on a subset of CD34+ cells in human fetal liver, bone marrow, and blood as demonstrated by flow cytometric analyses. In this study, we have further assessed the expression of AC133 on CD34+ cells in hemopoietic samples and found that there was a highly significant difference between normal bone marrow and cord blood versus aphereses (p <0.0001) but not between bone marrow and cord blood. Most of the clonogenic cells (67%) were contained in the CD34+AC133+ fraction. Compared with cultures of the CD34+AC133- cells, generation of progenitor cells in long-term culture on bone marrow stroma was consistently 10- to 100-fold higher in cultures initiated with CD34+AC133+ cells and was maintained for the 8-10 weeks of culture. Only the CD34+AC133+ cells were capable of repopulating NOD/SCID mice. Human cells were detectable as early as day 20, with increased levels (67%) apparent 40 days post-transplantation. Five thousand CD34+AC133+ cells engrafted about 20% of the mice, while no engraftment was observed in animals transplanted with up to 1.2 x 10(5) CD34+AC133- cells. The CD34+AC133+ population was also enriched (seven-fold) in dendritic cell precursors, and the dendritic cells generated were functionally active in a mixed lymphocyte reaction assay. AC133+ cells should be useful in the study of cellular and molecular mechanisms regulating primitive hemopoietic cells.


Subject(s)
Antigens, CD34 , Dendritic Cells/cytology , Glycoproteins/physiology , Hematopoiesis/physiology , Hematopoietic Stem Cells/cytology , Peptides/physiology , AC133 Antigen , Animals , Antigens, CD , Cell Culture Techniques , Fetal Blood/cytology , Flow Cytometry , Humans , Mice , Mice, Inbred NOD , Mice, SCID , Time Factors
14.
J Med Chem ; 41(26): 5265-71, 1998 Dec 17.
Article in English | MEDLINE | ID: mdl-9857094

ABSTRACT

A number of novel guanine derivatives containing heterocyclic moieties at the O6-position have been synthesized using a purine quaternary salt which reacts with alkoxides under mild conditions. Initially O6-substituents were investigated in which the benzene ring of the known agent, O6-benzylguanine, was replaced by unsubstituted heterocyclic rings. The ability of these agents to inactivate the DNA repair protein O6-alkylguanine-DNA alkyltransferase (ATase), both as pure recombinant protein and in the human lymphoblastoid cell line Raji, has been compared with that of O6-benzylguanine. The present paper focuses on O6-substituents with basic rings, and under standard conditions several of them proved more effective than benzyl for inactivation of both recombinant and Raji ATase. Among the pyridine derivatives, the 2-picolyl compound 7 is not very active in contrast to the 3- and 4-picolyl compounds, and this influenced our choice of isomers of other basic ring systems for study. Since halogen substitution in the thiophene ring considerably increased the activity (17 versus 6), similar modifications in the pyridine series were examined. The more polar O6-substituents in this study are on the whole compatible with the stereochemical requirements of the ATase protein, and their pharmacological properties may be valuable in subsequent in vivo investigations, particularly the thenyl (6), 5-thiazolylmethyl (12), 5-bromothenyl (17), and 2-chloro-4-picolyl (21) derivatives.


Subject(s)
Enzyme Inhibitors/chemical synthesis , Guanine/analogs & derivatives , Guanine/chemical synthesis , O(6)-Methylguanine-DNA Methyltransferase/antagonists & inhibitors , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Guanine/chemistry , Guanine/pharmacology , Humans , Recombinant Proteins/antagonists & inhibitors , Tumor Cells, Cultured
15.
Br J Cancer ; 78(9): 1128-33, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9820167

ABSTRACT

A study was made of the relationship between the intrinsic radiosensitivity of human cervical tumours and the expression of the DNA repair enzyme human apurinic/apyrimidinic endonuclease (HAP1). The radiosensitivity of clonogenic cells in tumour biopsies was measured as surviving fraction at 2 Gy (SF2) using a soft agar assay. HAP1 expression levels were determined after staining of formalin-fixed paraffin-embedded tumour sections with a rabbit antiserum raised against recombinant HAP1. Both measurements were obtained on pretreatment biopsy material. All 25 tumours examined showed positive staining for HAP1, but there was heterogeneity in the level of expression both within and between tumours. The average coefficients of variation for intra- and intertumour heterogeneity were 62% and 82% respectively. There was a moderate but significant positive correlation between the levels of HAP1 expression and SF2 (r = 0.60, P = 0.002). Hence, this study shows that there is some relationship between intrinsic radiosensitivity and expression of a DNA repair enzyme in cervical carcinomas. The results suggest that this type of approach may be useful in the development of rapid predictive tests of tumour radiosensitivity.


Subject(s)
Carbon-Oxygen Lyases/metabolism , DNA Repair , Nuclear Proteins/metabolism , Radiation Tolerance/physiology , Uterine Cervical Neoplasms/drug therapy , Uterine Cervical Neoplasms/enzymology , Animals , CHO Cells/metabolism , Cricetinae , DNA-(Apurinic or Apyrimidinic Site) Lyase , Deoxyribonuclease IV (Phage T4-Induced) , Female , Humans , Immunohistochemistry , Rabbits , Rats , Tumor Suppressor Protein p53/biosynthesis , Uterine Cervical Neoplasms/pathology
16.
Mol Cell Biol ; 18(10): 5828-37, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9742100

ABSTRACT

Alkylpurine-DNA-N-glycosylase (APNG) null mice have been generated by homologous recombination in embryonic stem cells. The null status of the animals was confirmed at the mRNA level by reverse transcription-PCR and by the inability of cell extracts of tissues from the knockout (ko) animals to release 3-methyladenine (3-meA) or 7-methylguanine (7-meG) from 3H-methylated calf thymus DNA in vitro. Following treatment with DNA-methylating agents, increased persistence of 7-meG was found in liver sections of APNG ko mice in comparison with wild-type (wt) mice, demonstrating an in vivo phenotype for the APNG null animals. Unlike other null mutants of the base excision repair pathway, the APNG ko mice exhibit a very mild phenotype, show no outward abnormalities, are fertile, and have an apparently normal life span. Neither a difference in the number of leukocytes in peripheral blood nor a difference in the number of bone marrow polychromatic erythrocytes was found when ko and wt mice were exposed to methylating or chloroethylating agents. These agents also showed similar growth-inhibitory effects in primary embryonic fibroblasts isolated from ko and wt mice. However, treatment with methyl methanesulfonate resulted in three- to fourfold more hprt mutations in splenic T lymphocytes from APNG ko mice than in those from wt mice. These mutations were predominantly single-base-pair changes; in the ko mice, they consisted primarily of AT-->TA and GC-->TA transversions, which most likely are caused by 3-meA and 3- or 7-meG, respectively. These results clearly show an important role for APNG in attenuating the mutagenic effects of N-alkylpurines in vivo.


Subject(s)
DNA Glycosylases , Hypoxanthine Phosphoribosyltransferase/genetics , Methyl Methanesulfonate/toxicity , Mutagens/toxicity , N-Glycosyl Hydrolases/physiology , Animals , Bone Marrow Cells/drug effects , Cells, Cultured , Dacarbazine/analogs & derivatives , Dacarbazine/pharmacology , Erythrocytes/drug effects , Ethylnitrosourea/analogs & derivatives , Ethylnitrosourea/pharmacology , Female , Fibroblasts/drug effects , Guanine/analogs & derivatives , Guanine/metabolism , Leukocyte Count/drug effects , Liver/metabolism , Male , Mice , Mice, Inbred C57BL , Mice, Inbred DBA , Mice, Knockout , Mutation , N-Glycosyl Hydrolases/genetics , N-Glycosyl Hydrolases/metabolism , Temozolomide
17.
Gene Ther ; 5(6): 835-41, 1998 Jun.
Article in English | MEDLINE | ID: mdl-9747464

ABSTRACT

Retroviral transduction was used to introduce cDNAs encoding two mutants of human O6-alkylguanine-DNA alkyltransferase (hAT), one of which (hATPA) is 16 times more resistant to O6-benzylguanine (O6-beG), and the other (hATPA/GA) which is almost totally refractory to inactivation relative to the wild-type protein, into K562 human erythroleukaemic cells. A colony-forming assay was used to demonstrate significant protection (P < 0.001) against mitozolomide or temozolomide toxicity in K562 clones expressing either hAT mutant, as determined from an in vitro assay of activity. However, protection against these agents was reduced in hATPA expressing cells in the presence of 1 microM O6-beG and was lost in the presence of 20 microM O6-beG while cells expressing hATPA/GA retained protection even in the presence of 20 microM O6-beG (P < 0.001). Using primary human cord blood-derived CD34+ haemopoietic cells in which PCR analysis indicated that up to 70% of progenitors were transduced with retroviral constructs harbouring hATPA/GA, we observed significant protection of the granulocyte-macrophage colony-forming cells against mitozolomide (P < 0.05) and temozolomide (P < 0.001) induced toxicity in the presence of O6-beG. These findings indicate that retrovirus-mediated expression of hATPA/GA in primitive primary human haemopoietic cells is possible and does provide O6-beG-resistant protection for these cells. Using this strategy in patients may simultaneously permit attenuated myelosuppression and increased sensitivity of tumour cells to the effects of O6-alkylating agent chemotherapy. These data, taken together with the study reported by Chinnasamy et al in the accompanying article in this issue showing reduced toxicity and clastogenicity in murine haemopoietic progenitors, make a compelling case to test this strategy clinically.


Subject(s)
Antineoplastic Agents, Alkylating/toxicity , Gene Transfer Techniques , Genetic Vectors , Hematopoietic Stem Cells , O(6)-Methylguanine-DNA Methyltransferase/genetics , Retroviridae , Antigens, CD34 , Cell Line , Cell Survival , Dacarbazine/analogs & derivatives , Dacarbazine/toxicity , Guanine/analogs & derivatives , Humans , Nitrogen Mustard Compounds/toxicity , Polymerase Chain Reaction , Temozolomide
18.
Gene Ther ; 5(6): 842-7, 1998 Jun.
Article in English | MEDLINE | ID: mdl-9747465

ABSTRACT

Murine bone marrow cells were transduced ex vivo with a retrovirus encoding an O6-benzylguanine (O6-beG) insensitive, double mutant form of the human DNA repair protein O6-alkylguanine-DNA alkyltransferase (hATPA/GA). In animals reconstituted with the transduced bone marrow, about 50% of cells in the multipotent spleen colony-forming cells (CFU-S) and lineage restricted granulocyte-macrophage (GM-CFC) haemopoietic progenitor populations were found to be carrying the transgene and this correlated with the frequency of bone marrow cells and spleen colonies which stained positive for hATPA/GA by immunocyto-chemistry. Expression of hATPA/GA was associated with significant in vivo protection of both CFU-S (P = 0.001) and GM-CFC (P < 0.024) against the toxicity of the antitumour methylating agent, temozolomide, given in combination with O6-beG. Expression of hATPA/GA also led to a reduction in the frequency of combined O6-beG/temozolomide-induced micronuclei seen in polychromatic erythrocytes (P < 0.003). This study is the first to demonstrate in vivo protection of multipotent haemopoietic progenitors against the toxic and clastogenic effects of an O6-alkylating agent in the presence of O6-beG. It also represents the first report of reduced clastogenesis as a consequence of expression of an O6-beG-resistant ATase. In the accompanying article we report hATPA/GA-mediated resistance of human CD34+ haemopoietic progenitors to combined O6-beG/O6-alkylating agent toxicity. Together these two reports suggest that a gene therapy strategy whereby protection of normal haemopoietic tissue may be combined with O6-beG-mediated tumour sensitisation may be efficacious in achieving an increase in therapeutic index.


Subject(s)
Antineoplastic Agents, Alkylating/toxicity , Dacarbazine/analogs & derivatives , Gene Transfer Techniques , Genetic Vectors , O(6)-Methylguanine-DNA Methyltransferase/genetics , Retroviridae , Stem Cells , Animals , Bone Marrow Cells , Cell Survival , Dacarbazine/toxicity , Gene Expression , Male , Mice , Mice, Inbred Strains , Polymerase Chain Reaction , Spleen/cytology , Temozolomide
19.
Mutat Res ; 416(1-2): 1-10, 1998 Aug 07.
Article in English | MEDLINE | ID: mdl-9725988

ABSTRACT

The murine bone marrow micronucleus assay has been used to examine (1) the potentiation of fotemustine and streptozotocin induced-clastogenicity by the O6-alkylguanine-DNA alkyltransferase (ATase) inactivator O6-benzylguanine (O6-beG) and (2) the level of protection afforded against this potentiation by retrovirus-mediated expression of an O6-beG-resistant mutant of human ATase (haTPA/GA) in mouse bone marrow. Both fotemustine and streptozotocin induced significantly higher levels of micronucleated polychromatic erythrocytes (p < 0.001 for the highest doses studied) compared to those seen in vehicle-treated animals. The number of micronuclei produced by either agent was dramatically elevated by pretreatment with O6-beG (p < 0.001). Furthermore, in myeloablated mice reconstituted with bone marrow expressing the O6-beG-resistant hATPA/GA as a result of retroviral gene transfer, the frequency of micronucleus formation following exposure of mice to otherwise clastogenic doses of fotemustine or streptozotocin, in the presence of O6-beG, wash highly significantly reduced (p < 0.001 for both agents) relative to that in mock transduced controls. These data clearly implicate O6-chloroethyl- and O6-methylguanine as clastogenic lesions in vivo and establish ATase as a major protective mechanism operating to reduce the frequency of such damage. The potentiation of drug induced clastogenicity by O6-beG suggests that the clinical use of this inactivator in combination with O6-alkylating agents, could substantially increase the risk of therapy related malignancy. Nevertheless the use of hATPA/GA as a protective mechanism via gene therapy may overcome this risk.


Subject(s)
Alkylating Agents/pharmacology , Bone Marrow Cells/drug effects , Bone Marrow Cells/metabolism , DNA Repair/drug effects , Mutagens/pharmacology , Alkyl and Aryl Transferases/antagonists & inhibitors , Alkyl and Aryl Transferases/genetics , Alkylating Agents/administration & dosage , Animals , Bone Marrow Transplantation , Drug Synergism , Enzyme Inhibitors/administration & dosage , Enzyme Inhibitors/pharmacology , Female , Gene Expression , Guanine/administration & dosage , Guanine/analogs & derivatives , Guanine/pharmacology , Humans , Male , Mice , Micronucleus Tests , Mutagens/administration & dosage , Mutation , Nitrosourea Compounds/administration & dosage , Nitrosourea Compounds/pharmacology , Organophosphorus Compounds/administration & dosage , Organophosphorus Compounds/pharmacology , Streptozocin/administration & dosage , Streptozocin/pharmacology
20.
Carcinogenesis ; 18(10): 1883-8, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9363995

ABSTRACT

Here we confirm and extend our previous studies demonstrating that the mutagenic potency of 1,2-dibromoethane (DBE) and dibromomethane (DBM) is markedly enhanced (not prevented) in bacteria expressing the O6-alkylguanine-DNA alkyltransferase (ATase) encoded by the Escherichia coli ogt gene. We demonstrate that, in close parallel with mutagenesis, the Ogt ATase sensitizes the bacteria to the lethal effects of these carcinogens, suggesting that one or more of the potentially mutagenic lesions induced by DBE and DBM in the presence of Ogt has additional lethal capacity. We further demonstrate that the sensitization to both lethality and mutagenesis by DBE and DBM is a property shared by other DNA alkyltransferases. This objective was accomplished by quantifying the induction of mutations and lethal events in ogt- ada- E. coli expressing an exogenous bacterial or mammalian ATase from a multicopy plasmid. Mammalian recombinant ATases enhanced the lethal and mutagenic actions of DBE and suppressed the lack of sensitivity of the vector-transformed bacteria to DBM. In most cases the order of effectiveness of the ATases ranked: murine > human > Ogt > rat. Further comparisons included the full-length Ada ATase from E. coli and a truncated Ada version (T-ada) that retains the O6-methylguanine binding domain of the protein. The full-length Ada ATase was effective in enhancing the lethality but not the mutagenicity induced by DBE and DBM. The T-ada ATase provided less sensitization than Ada to lethality by DBE, but of the three bacterial ATases T-ada yielded the highest sensitization to mutagenesis by this compound. T-ada and Ada ATases were in general less effective than the mammalian versions, with the exception of the rat recombinant ATase. The effectiveness of the different mammalian and bacterial ATases in promoting the deleterious actions of dibromoalkanes was compared with the effectiveness of these proteins in suppressing the lethal and mutagenic effects induced by N-nitroso-N-methylurea. The ability to sensitize E. coli to the lethal and mutagenic effects of DBE and DBM seems restricted to DNA alkyltransferase, since overexpression of thioredoxin (Trx) or glutaredoxin (Grx1) in ogt- ada- cells showed no effect, in spite of the reported potential of bioactive dihaloethane-derived species to alkylate Trx.


Subject(s)
Carcinogens/toxicity , Escherichia coli Proteins , Escherichia coli/drug effects , Ethylene Dibromide/toxicity , Genes, Bacterial , Hydrocarbons, Brominated/toxicity , Insecticides/toxicity , O(6)-Methylguanine-DNA Methyltransferase/physiology , Animals , Bacterial Proteins , Escherichia coli/enzymology , Escherichia coli/genetics , Humans , Methylnitrosourea/toxicity , Mice , Plasmids/genetics , Rats , Transcription Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...